■人乳头瘤病毒(HPV)是宫颈鳞状细胞癌发展的主要危险因素,和E6癌蛋白和E7癌蛋白是病毒基因组及其致癌潜力的重要组成部分。已知HPV16的不同病毒变体具有不同的病理和对肿瘤发展的影响,尽管对南美变体的研究很少。
■因此,本研究旨在分析美国国家生物技术信息中心(NCBI)数据库中南美洲20种全基因组变异中HPV16的基因组多样性.
■我们进行了一项描述性研究,以表征HPV16变体中E6和E7基因的多态性区域,使用软件进行基因组数据和单核苷酸多态性(SNP)分析等进行系统发育分析。
■分析的变异包括与癌症相关的六个SNP(A131G,G145T,C335T,T350G,C712A,和T732C)和显著变异(798个核苷酸取代)。尽管如此,变异体的遗传多样性较低。鉴定出18种意义不明确的变体(VUS)。其中10个在编码E6区中,8个在编码E7区中。由于其在子宫颈癌中的病理学,所以谱系D变体的患病率令人担忧,并且需要对其在人群中的患病率进行更多的研究和流行病学警惕。
■本研究中获得的数据可能有助于对HPV16的南美变体及其致病性的未来研究,以及治疗方法的发展。
UNASSIGNED: Human papillomavirus (HPV) is the main risk factor for the development of squamous cell cervical cancer, and E6 oncoprotein and E7 oncoprotein are important components of the viral genome and its oncogenic potential. It is known that different viral variants of HPV16 have different pathology and impact on the development of neoplasia, although few studies have been performed on South American variants.
UNASSIGNED: Therefore, the present study aimed to analyze in silico the genomic diversity of HPV16 in 20 complete genome variants of South America in the National Center for Biotechnology Information (NCBI) database.
UNASSIGNED: We performed a descriptive study to characterize the polymorphic regions of the E6 and E7 genes in HPV16 variants, using
software for genomic data and single nucleotide polymorphism (SNP) analysis and others for phylogenetic analysis.
UNASSIGNED: The variants analyzed included six SNPs linked to cancer (A131G, G145T, C335T, T350G, C712A, and T732C) and significant variation (798 nucleotide substitutions). Despite this, the variants showed low genetic diversity. Eighteen variants of unclear significance (VUS) were identified, 10 of which were in the coding E6 regions and 8 in the coding E7 regions. The prevalence of lineage D variants is of concern due to their pathology in cervical cancer and requires more research and epidemiological vigilance regarding their prevalence in the population.
UNASSIGNED: The data obtained in this study may contribute to future research on South American variants of HPV16, their pathogenicity, and the development of treatments.